Johnson & Johnson’s Oral IL-23 Receptor Blocker Shows Promise in Moderate-to-severe Plaque PsO
JNJ-2113, Johnson & Johnson’s oral IL-23 receptor blocker, showed positive results in moderate-to-severe plaque psoriasis, according to the Phase 2b FRONTIER 1 study published in the New England Journal of Medicine. JNJ-2113 is the first and only investigational targeted oral peptide inhibitor designed to block the IL-23 receptor. IL-23 plays a critical role in pathogenic T-cell […]